Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Oral semaglutide for the treatment of type 2 diabetes

Hedrington, Maka S., Davis, Stephen N. · 2019 · Expert Opinion on Pharmacotherapy

Abstract

Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists are highly potent antihyperglycemic drugs that impose low risk of hypoglycemia and also result in body weight reduction. Currently, all approved members of the class require administration by injection. Areas covered: This manuscript reviews oral semaglutide—an experimental GLP-1 receptor agonist in phase-3 clinical development. Available pharmacological and clinical data of the drug are reviewed, and important end-points described. Expert opinion: Oral peptide delivery has become possible with the discovery of absorption enhancers. The clinical development program of once-daily oral semaglutide has shown superiority in reducing glycosylated hemoglobin and body weight in comparison with placebo and active comparators (sitagliptin, liraglutide, and empagliflozin). Safety and tolerability of oral semaglutide is in line with injectable members of the class. Delayed gastric emptying, local increase in pH, and enhanced absorption do not seem to affect the exposure of a number of other oral drugs that have been tested (metformin, digoxin, oral contraceptive ethinylestradiol/levonorgestrel, lisinopril, warfarin, furosemide and rosuvastatin). Clinical questions for further investigation include the effectiveness and safety of oral semaglutide in cardiovascular indications.

Overview

Integrity signals

Registry

Crossref · 10.1080/14656566.2018.1552258

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 17 references

Research works printed but not linked: 9

  1. Armstrong C., 2017, Am Fam Physician, 95, 40
  2. Buckley ST, 2017, Diabetes, 66, 1206
  3. Baekdal TA, Blicher TM, 2017, Diabetes, 66
  4. Granhall C, 2017, Diabetes, 66
  5. Connor A, Borregaard J, 2017, Diabetes, 66
  6. Baekdal TA, Borregaard J, 2017, Diabetes, 66
  7. Thomsen M, 2017, Diabetes, 66
  8. Jordy AB, 2018, Diabetes, 67
  9. Borregaard J, 2017, Diabetes, 66

Cited by

See all 44

Metadata

Authors
Hedrington, M. S., & Davis, S. N.
Affiliations
University of Maryland, Baltimore (US)
Corresponding author
Davis, Stephen N.
Venue
Expert Opinion on Pharmacotherapy
Published
2018-11-30
Volume
20
Issue
2
Pages
133-141
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W2903342525
Cited by
44
References
17
Citations by year
2026: 4 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 9 · 2020: 10 · 2019: 9
FWCI
5.10
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
not funded
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
oral semaglutide, GLP-1 receptor agonists, type 2 diabetes, absorption enhancers, HbA1c, weight loss, drug-drug interactions, drug safety and tolerability, cardiovascular effects, antihyperglycemic therapy
MeSH terms
Sitagliptin Phosphate, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glucosides, Humans, Hypoglycemia, Hypoglycemic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral semaglutide for the treatment of type 2 diabetes. https://app.cochat.ai/papers/10.1080/14656566.2018.1552258
The paper
Hedrington, M. S., & Davis, S. N. (2019). Oral semaglutide for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2018.1552258

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.